Pelage Pharma has secured a $16.75M Series A investment from notable investors including GV, Main Street Advisors, Visionary Ventures, and YK Bioventures on 27 February 2024. The company is focused on the Health Care and Pharmaceutical industries and is dedicated to providing a clinically validated solution for individuals grappling with the emotional impact or social stigma associated with hair loss. Its non-invasive, topical small molecule drug platform is designed to activate hair follicle stem cells and promote substantial hair growth. Pelage Pharma's innovative approach to addressing common yet impactful health concerns presents an enticing opportunity for potential investors seeking to support groundbreaking solutions in the healthcare sector.
No recent news or press coverage available for Pelage Pharmaceuticals.